Atlas Trials

A Real-World Study of Pyrotinib Maleate in the Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer With Rare Mutations in HER2

Clinical trial NCT05411276 · UNKNOWN

Trial details

NCT number
NCT05411276
Sponsor
Beijing Chest Hospital
Status
UNKNOWN
Study type
OBSERVATIONAL
HER2 Mutant Non-small Cell Lung Cancer
Start date
2022-06-30
Primary completion
2023-12-31
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.